NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,013 DKK | +0.42% |
|
+3.21% | +45.01% |
| 06:37am | China Approves Novo Nordisk's Injection for Long-term Weight Management | MT |
| 06-25 | Health Care Up as Novo Nordisk Gets China OK -- Health Care Roundup | DJ |
| Sales 2024 * | 291B 41.76B 3,296B | Sales 2025 * | 352B 50.42B 3,980B | Capitalization | 4,559B 653B 51,577B |
|---|---|---|---|---|---|
| Net income 2024 * | 105B 15.01B 1,185B | Net income 2025 * | 128B 18.3B 1,445B | EV / Sales 2024 * | 15.7 x |
| Net Debt 2024 * | 22.09B 3.16B 250B | Net cash position 2025 * | 6.04B 865M 68.27B | EV / Sales 2025 * | 12.9 x |
| P/E ratio 2024 * |
44
x | P/E ratio 2025 * |
36
x | Employees | 66,015 |
| Yield 2024 * |
1.15% | Yield 2025 * |
1.41% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +0.42% | ||
| 1 week | +3.21% | ||
| Current month | +9.87% | ||
| 1 month | +9.20% | ||
| 3 months | +13.96% | ||
| 6 months | +45.80% | ||
| Current year | +45.01% |
1 week
973.60
1 031.00
1 month
902.301 031.00
Current year
688.901 031.00
1 year
504.701 031.00
3 years
256.651 031.00
5 years
157.501 031.00
10 years
107.921 031.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/90 | |
| Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 18/03/15 |
Helge Lund
CHM | Chairman | 61 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/24 | 1,012 | +0.32% | 62 899 |
| 25/06/24 | 1,022 | +3.61% | 1,096,260 |
| 24/06/24 | 986.4 | -0.23% | 277,650 |
| 21/06/24 | 988.7 | +0.18% | 764,373 |
| 20/06/24 | 986.9 | +0.62% | 158,768 |
Delayed Quote London S.E., June 26, 2024 at 11:52 am
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.19% | 815B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +18.83% | 247B | |
| +3.19% | 229B | |
| +13.75% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B | |
| +1.01% | 122B |
- Stock Market
- Equities
- NOVO B Stock
- 0QIU Stock
